In September 2023, FDA placed "Thymosin Beta-4, Fragment (LKKTETQ)," the substance sold as TB-500, on Category 2 of its interim 503A bulk drug substances list, meaning FDA identified significant safety concerns and would not permit licensed compounding pharmacies to use it
For the growing number of patients and practitioners focused on anti-aging peptide therapy, this update could mark a watershed moment in treatment access
Circ Res 116:15611578 Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B, Rotkvic I, Mise S, Zoricic I et al (1997) Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats
What are the possible side effects of FIRDAPSE
Does anyone have experience with GHK-CU
BPC-157 is one of the most widely used peptides in regenerative medicine, prized for its remarkable effects on gut healing, tissue repair, and inflammation reduction